Cargando…

Taxifolin Targets PI3K and mTOR and Inhibits Glioblastoma Multiforme

Glioblastoma multiforme (GBM), the most common malignant primary brain tumor, has a very poor prognosis. With increasing knowledge of tumor molecular biology, targeted therapies are becoming increasingly integral to comprehensive GBM treatment strategies. mTOR is a key downstream molecule of the PI3...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yao, Weiqi, Gong, Hongyun, Mei, Heng, Shi, Lei, Yu, Jinming, Hu, Yu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8403040/ https://www.ncbi.nlm.nih.gov/pubmed/34462635 http://dx.doi.org/10.1155/2021/5560915

Ejemplares similares

mTOR Modulates Intercellular Signals for Enlargement and Infiltration in Glioblastoma Multiforme
por: Ryskalin, Larisa, et al.
Publicado: (2020)

Neuronal Activity, Mitogens, and mTOR: Overcoming the Hurdles for the Treatment of Glioblastoma Multiforme
por: Maiese, Kenneth
Publicado: (2015)

Effect of VEGFR, PDGFR and PI3K/mTOR Targeting in Glioblastoma
por: PURCARU, S.O., et al.
Publicado: (2015)

PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma
por: Li, Xiaoman, et al.
Publicado: (2016)

Wnt and PI3K/Akt/mTOR Survival Pathways as Therapeutic Targets in Glioblastoma
por: Barzegar Behrooz, Amir, et al.
Publicado: (2022)

Sinomenine ester derivative inhibits glioblastoma by inducing mitochondria-dependent apoptosis and autophagy by PI3K/AKT/mTOR and AMPK/mTOR pathway
por: Zheng, Xiangjin, et al.
Publicado: (2021)

Carnosine inhibits glioblastoma growth independent from PI3K/Akt/mTOR signaling
por: Oppermann, Henry, et al.
Publicado: (2019)

The New PI3K/mTOR Inhibitor GNE-477 Inhibits the Malignant Behavior of Human Glioblastoma Cells
por: Wang, Yixuan, et al.
Publicado: (2021)

PI3K/AKT/mTOR Pathway in Angiogenesis
por: Karar, Jayashree, et al.
Publicado: (2011)

Targeting PI3K/mTOR Signaling in Cancer
por: Arcaro, Alexandre
Publicado: (2014)

PI3K/AKT/mTOR-Targeted Therapy for Breast Cancer
por: Zhu, Kunrui, et al.
Publicado: (2022)

miR-196b regulates gastric cancer cell proliferation and invasion via PI3K/AKT/mTOR signaling pathway
por: LI, NA, et al.
Publicado: (2016)

Molecular mechanisms of tumor resistance to PI3K-mTOR-targeted therapy
por: Tan, Jing, et al.
Publicado: (2013)

Targeting PI3K/Akt/mTOR Signaling in Cancer
por: Porta, Camillo, et al.
Publicado: (2014)

Multipoint targeting of the PI3K/mTOR pathway in mesothelioma
por: Zhou, S, et al.
Publicado: (2014)

PI3K/Akt/mTOR inhibitors in breast cancer
por: Lee, Joycelyn JX, et al.
Publicado: (2015)

The Role of PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma Metabolism
por: Tian, Ling-Yu, et al.
Publicado: (2023)

EGFR and mTOR as therapeutic targets in glioblastoma
por: Ronellenfitsch, Michael W., et al.
Publicado: (2019)

Dual mTOR/PI3K inhibition limits PI3K-dependent pathways activated upon mTOR inhibition in autosomal dominant polycystic kidney disease
por: Liu, Yang, et al.
Publicado: (2018)

Resistin targets TAZ to promote osteogenic differentiation through PI3K/AKT/mTOR pathway
por: Shang, JingJing, et al.
Publicado: (2023)

Taxifolin, Extracted from Waste Larix olgensis Roots, Attenuates CCl(4)-Induced Liver Fibrosis by Regulating the PI3K/AKT/mTOR and TGF-β1/Smads Signaling Pathways
por: Liu, Xinglong, et al.
Publicado: (2021)

Combined inhibition of AKT/mTOR and MDM2 enhances Glioblastoma Multiforme cell apoptosis and differentiation of cancer stem cells
por: Daniele, Simona, et al.
Publicado: (2015)

Targeting the PI3K/Akt/mTOR Pathway – Beyond Rapalogs
por: Markman, Ben, et al.
Publicado: (2010)

AKTivation of PI3K/AKT/mTOR signaling pathway by KSHV
por: Bhatt, Aadra P., et al.
Publicado: (2013)

Targeting the PI3K/mTOR Pathway in Pediatric Hematologic Malignancies
por: Tasian, Sarah K., et al.
Publicado: (2014)

The Role of PI3K/Akt/mTOR Signaling in Gastric Carcinoma
por: Matsuoka, Tasuku, et al.
Publicado: (2014)

Targeting the PI3K-AKT-mTOR signaling network in cancer
por: Khan, Khurum H., et al.
Publicado: (2013)

Outlook on PI3K/AKT/mTOR inhibition in acute leukemia
por: Fransecky, Lars, et al.
Publicado: (2015)

In vitro effects of PI3K/mTOR inhibition in canine hemangiosarcoma
por: Pyuen, Alex A., et al.
Publicado: (2018)

PI3K/AKT/mTOR pathway in pulmonary carcinoid tumours
por: Zhang, Zixuan, et al.
Publicado: (2017)

Targeting RTK-PI3K-mTOR Axis in Gliomas: An Update
por: Colardo, Mayra, et al.
Publicado: (2021)

Co-Targeting PIM Kinase and PI3K/mTOR in NSCLC
por: Moore, Gillian, et al.
Publicado: (2021)

Targeting the PI3K/Akt/mTOR Pathway in Hepatocellular Carcinoma
por: Sun, Eun Jin, et al.
Publicado: (2021)

PI3K/AKT/mTOR pathway in tumor progression of oligodendrogliomas
por: Lisi, Lucia
Publicado: (2020)

Roles of PI3K/AKT/mTOR Axis in Arteriovenous Fistula
por: Ratti, Stefano, et al.
Publicado: (2022)

Naringin inhibits colorectal cancer cell growth by repressing the PI3K/AKT/mTOR signaling pathway
por: Cheng, Hongyun, et al.
Publicado: (2020)

BET protein inhibition evidently enhances sensitivity to PI3K/mTOR dual inhibition in intrahepatic cholangiocarcinoma
por: Miao, Xiaolong, et al.
Publicado: (2021)

Epithelial membrane protein 1 promotes glioblastoma progression through the PI3K/AKT/mTOR signaling pathway
por: Miao, Lifeng, et al.
Publicado: (2019)

Tivantinib Hampers the Proliferation of Glioblastoma Cells via PI3K/Akt/Mammalian Target of Rapamycin (mTOR) Signaling
por: Wu, Yukun, et al.
Publicado: (2019)

Chitosan oligosaccharide suppresses osteosarcoma malignancy by inhibiting CEMIP via the PI3K/AKT/mTOR pathway
por: Sim, IlJin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_mpkgp79vm1nndeeva6f69fmtji